Assessing the chiral switch: Approval and use of single-enantiomer drugs, 2001 to 2011

American Journal of Managed Care

Volumn 20, Issue 3, 2014, Pages

  Gellad, Walid F ^a,b,c   Choi, Phillip ^b   Mizah, Margaret ^a   Good, Chester B ^a,b   Kesselheim, Aaron S ^d,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c RAND CORPORATION   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARFORMOTEROL; ARMODAFINIL; DEXMETHYLPHENIDATE; DRUG; ESCITALOPRAM; ESOMEPRAZOLE; ESZOPICLONE; LANSOPRAZOLE; LEVOCETIRIZINE; LEVOLEUCOVORIN; SINGLE ENANTIOMER DRUG; UNCLASSIFIED DRUG; ANTIDOTE; AZABICYCLO DERIVATIVE; BENZHYDRYL DERIVATIVE; BRONCHODILATING AGENT; CENTRAL STIMULANT AGENT; CETIRIZINE; ETHANOLAMINE DERIVATIVE; FORMOTEROL; GENERIC DRUG; HISTAMINE H1 RECEPTOR ANTAGONIST; HYPNOTIC SEDATIVE AGENT; PIPERAZINE DERIVATIVE; PROTON PUMP INHIBITOR; WAKEFULNESS PROMOTING AGENT;

ARTICLE; CHIRAL SWITCH; CHIRALITY; DRUG APPROVAL; DRUG COST; ENANTIOMER; MEDICAID; PRESCRIPTION; PRIORITY JOURNAL; RACEMIC MIXTURE; RETROSPECTIVE STUDY; CHEMISTRY; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HUMAN; PATENT; STATISTICS AND NUMERICAL DATA; STEREOISOMERISM; UNITED STATES;

ANTIDOTES; AZABICYCLO COMPOUNDS; BENZHYDRYL COMPOUNDS; BRONCHODILATOR AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CETIRIZINE; DEXLANSOPRAZOLE; DEXMETHYLPHENIDATE; DRUG APPROVAL; DRUG PRESCRIPTIONS; DRUGS, GENERIC; ESOMEPRAZOLE; ETHANOLAMINES; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; HYPNOTICS AND SEDATIVES; LEVOLEUCOVORIN; MEDICAID; PATENTS AS TOPIC; PIPERAZINES; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; STEREOISOMERISM; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WAKEFULNESS-PROMOTING AGENTS;

EID: 84897418323     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Tucker GT. Chiral switches. Lancet. 2000;355(9209):1085-1087. (Pubitemid 30162817)
2. Peter K, Vollhardt C, Schore NE. Organic Chemistry. 5th ed. New York, NY: WH Freeman; 2005.
3. de Carvalho CCCR, da Fonseca MMR. Carvone: Why and how should one bother to produce this terpene. Food Chemistry. 2006;95(3):413-422.
4. Leitereg T, Guadagni D, Harris J, Mon T, Teranishi R. Evidence for the difference between the Odours of the Optical Isomers (4)- and (-)-carvone. Nature. 1971;230(5294):455-456.
5. Leitereg TJ, Guadagni DG, Harris J, Mon TR, Teranishi R. Chemical and sensory data supporting the difference between the odors of the enantiomeric carvones. J Agric Food Chem. 1971;19(4):785-787.
6. Andersson T. Single-isomer drugs: true therapeutic advances. Clin Pharmacokinet. 2004;43(5):279-285. (Pubitemid 38534751)
7. Caner H, Groner E, Levy L, Agranat I. Trends in the development of chiral drugs. Drug Discov Today. 2004;9(3):105-110. (Pubitemid 38198306)
8. Mendelson J, Uemura N, Harris D, et al. Human pharmacology of the methamphetamine stereoisomers. Clin Pharmacol Ther. 2006;80(4): 403-420. (Pubitemid 44479752)
9. Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov. 2002;1(10):753-768. (Pubitemid 37361560)
10. Berenson A. Shortage of Prilosec to Persist. New York Times. March 3, 2005.
11. Goozner M. The $800 Million Pill: The Truth behind the Cost of New Drugs. Berkeley: University of California Press; 2004.
12. Development of new stereoisomeric drugs. US Food and Drug Administration website. http://www.fda.gov/drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm122883.htm. Published May 1, 1992. Accessed January 6, 2013.
13. Avorn J. FDA standards - good enough for government work? N Engl J Med. 2005;353(10):969-972. (Pubitemid 41262330)
14. Stafford RS, Wagner TH, Lavori PW. New, but not improved? incorporating comparative-effectiveness information into FDA labeling. N Engl J Med. 2009;361(13):1230-1233.
15. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151(3):206-209.
16. Centers for Medicare & Medicaid Services. State Drug Utilization Data. http://medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/ Prescription-Drugs/Medicaid-Drug-Programs-Data-and-Resources.html. Accessed April 1, 2013.
17. US Food and Drug Administration Center for Drug Evaluation and Research. Esomeprazole (Nexium) Medical Review(s). NDA 21-153.2000.
18. Pharmaceutical Benefits under State Medical Assistance Programs. National Pharmaceutical Council website. http://www.npcnow.org/system/files/research/ download/2005-6%20Pharmaceutical-Benefits-Under-State-Medical-Assistance- Programs.pdf. Published 2006. Accessed June 20, 2013.
19. AstraZeneca. Annual Report and Form 20-F Information. 2011.
20. Forest Laboratories Inc. Annual Report, 2011. New York, NY: Forest Laboratories, Inc.
21. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev.2009.
22. McDonagh MS, Carson S, Thakurta S. Drug class review: proton pump inhibitors: final report update 5. Portland, OR; Oregon Health & Science University: May 2009.
23. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007(2):CD003244.
24. Kahrilas PJ, Falk GW, Johnson DA, et al. The Esomeprazole Study Investigators; Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther. 2000;14(10):1249-1258.
25. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96(3):656-665. (Pubitemid 32240711)
26. Lightdale CJ, Schmitt C, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci. 2006;51(5):852-857. (Pubitemid 44030802)
27. Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci. 2006;51(5):844-850. (Pubitemid 44030800)
28. US Food and Drug Administration Center for Drug Evaluation and Research. Dexlansoprazole (Kapidex) summary review. NDA 22-287.2009.
29. US Food and Drug Administration Center for Drug Evaluation and Research. Arformoterol (Brovana) summary review. NDA 21-912.2006.
30. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism - chronic treatment with L-dopa. N Engl J Med. 1969;280(7):337-345.
31. Hutt AJ, Velntova J. The chiral switch: the development of single enantiomer drugs from racemates. Acta Facultatis Pharmaceuticae Universitatis Comenianae 2003;50:7-23.
32. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421-429. (Pubitemid 32097260)
33. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. (Pubitemid 47026771)
34. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42(7):626-634.
35. Carrier MA. Provigil: a case study of anticompetitive behavior. Hastings Science & Technology Law Journal. 2011;3(2):441-452.
36. Staton T. How will Cephalon shift patients to Nuvigil? FiercePharma website. http://www.fiercepharma.com/story/how-will-cephalon-shiftpatients- nuvigil/2009-08-07. Published August 7, 2009. Accessed April 1, 2013.
37. Rockoff JD. How a drug maker tries to outwit generics. The Wall Street Journal. November 18, 2008.
38. Cephalon Inc. 10-K Quarterly Report. http://quicktake.morningstar.com/ stocknet/secdocuments.aspx?symbol=ceph. Published June 30, 2011. Accessed April 1, 2013.
39. Steinman MA, Chren MM, Landefeld CS. What's in a name? use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med. 2007;22(5):645-648. (Pubitemid 46941178)
40. Lobo F, Feldman R. Generic drug names and social welfare. J Health Polit Policy Law. 2013;38(3):573-597.
41. Angell M. Excess in the pharmaceutical industry. CMAJ. 2004; 171(12):1451-1453. (Pubitemid 39655824)
42. Elliott S, Ives N. Prescription drug ads come under criticism. New York Times. October 12, 2004.
43. Gladwell M. High prices. The New Yorker. October 25, 2004.
44. Stafford RS, Wagner TH, Lavori PW. New, but not improved? incorporating comparative-effectiveness information into FDA labeling. N Engl J Med. 2009;361(13):1230-1233.
45. Rajkumar R, Kesselheim AS. Balancing access and innovation: India's supreme court rules on imatinib. JAMA. 2013;310(3):263-264
46. Huskamp HA, Busch AB, Domino ME, Normand SL. Antidepressant reformulations: who uses them, and what are the benefits? Health Aff (Millwood). 2009;28(3):734-745.